share_log

Goldman Sachs Maintains Buy on Health Catalyst, Lowers Price Target to $18

Benzinga Real-time News ·  Aug 10, 2022 21:00

Goldman Sachs analyst Cindy Motz maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $29 to $18.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment